264 related articles for article (PubMed ID: 31483485)
21. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin SH; Logothetis CJ; Tu SM
Cancer Chemother Pharmacol; 2017 Sep; 80(3):583-589. PubMed ID: 28730293
[TBL] [Abstract][Full Text] [Related]
22. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
[TBL] [Abstract][Full Text] [Related]
23. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Antonarakis ES; Subudhi SK; Pieczonka CM; Karsh LI; Quinn DI; Hafron JM; Wilfehrt HM; Harmon M; Sheikh NA; Shore ND; Petrylak DP
Clin Cancer Res; 2023 Jul; 29(13):2426-2434. PubMed ID: 37058234
[TBL] [Abstract][Full Text] [Related]
24. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
Zhang L; Kandadi H; Yang H; Cham J; He T; Oh DY; Sheikh NA; Fong L
Cancer Immunol Res; 2020 Dec; 8(12):1496-1507. PubMed ID: 32967912
[TBL] [Abstract][Full Text] [Related]
25. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
26. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
[TBL] [Abstract][Full Text] [Related]
27. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
[TBL] [Abstract][Full Text] [Related]
28. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
[TBL] [Abstract][Full Text] [Related]
29. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
[TBL] [Abstract][Full Text] [Related]
30. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
31. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
[TBL] [Abstract][Full Text] [Related]
32. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
[TBL] [Abstract][Full Text] [Related]
33. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
[TBL] [Abstract][Full Text] [Related]
34. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
35. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
36. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
37. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
38. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
39. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
40. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]